Vivodyne

Our CEO Andrei Georgescu, Ph.D. and Chief Operating Officer Julie O'Shaughnessy spoke at the LSX USA Congress on leveraging #AI in #biotech and drug development. Great meeting everyone this week in Boston. Hope to see you all soon at the next event. #LSXCongress

Breakthrough translational discoveries face critical bottlenecks that limit their path to value-driving drug development. Inefficiencies in translation range from poor disease models, to underdeveloped delivery technology, to mismatched expectations for what constitutes validation. At #BioCenturyGrandRounds, the Translational Bottlenecks Session unpacked the strategies for overcoming these roadblocks: ➤ From causal biology to preclinical validation: What makes the grade in 2024? ➤ The human-first era is here: Is there still value in new animal models? ➤ Delivery on demand: Still the elephant in the room Registration is available on-site at Four Seasons Nashville, or register for a digital pass to watch recordings of the sessions at https://lnkd.in/gmhZ75vm. Thank you to our Grand Rounds I: Translational Bottlenecks panelists and moderators: Manuel Ascano, Vanderbilt University School of Medicine Lori Aschenbrenner, PhD, DABT, Labcorp Melissa Bonner, Nvelop Therapeutics Kevin Friedman, Kelonia Therapeutics Andrei Georgescu, Ph.D., Vivodyne Anika Gupta, PhD, GV (Google Ventures) Chris Hollowood, Syncona Limited Chaitan Khosla, Stanford University John Kuriyan, Vanderbilt University School of Medicine John Lepore, ProFound Therapeutics Patrick Lyden, Keck School of Medicine of the University of Southern California Nikhil Wagle, Genentech Douglas Williams, TriArm Therapeutics Matthew Wilson, Vanderbilt University Medical Center Carolyne Zimmermann, SonoThera

We’re here at BIO 2024 and excited to lead conversations that push the limits of what’s possible in drug development. Join us for two panel sessions! 🔬AI’s impact on Oncology Cancer Drug Development on Wednesday, June 5 at 3 pm. with our CEO, Andrei Georgescu, Ph.D. 💊How to De-Risk Drug Development from the Earliest Stages on Wednesday, June 5 at 11 am with our CCO, Susan Billings, Ph.D. #vivodyne #humandatabeforetheclinic #BIO2024 #innovateandcollaborate

🎙️Exclusive podcast release! Our CEO recently joined Yin He on the latest episode of the AWS Health Innovation Podcast. In this insightful conversation, Andrei Georgescu, Ph.D. delves into how Vivodyne enables human testing before clinical trials. Our innovative platform has the capacity to cultivate tens of thousands of human tissue models at scale, setting a new standard in the field. Key Highlights: 🔬 How our microfluidic platform revolutionizes drug discovery by providing unprecedented insights into human biology ⚡ The key innovation behind our bottom-up self-assembly approach to grow complex human tissues 🌱 How our platform aligns with ethical principles by displacing animal testing 🧠 The immense challenge we are tackling by enabling AI modeling of integrated human physiology 💡 Advice from our CEO for biotech entrepreneurs on embracing transformative innovation ... and so much more. 🔉 Listen on the Health Podcast Network, or wherever you listen to your podcasts: https://lnkd.in/dJcyhSPA #AWSHealthPod #Biotech #DrugDiscovery #MicrofluidicTechnology #HumanBiology #EthicalInnovation #BiotechStartup #DrugDevelopment #OrganOnAChip

We are excited to announce the promotion of Julie O'Shaughnessy to Chief Operating Officer at Vivodyne! Julie has demonstrated exceptional leadership in scaling our team, optimizing our operational framework, and fostering a positive organizational culture. With her as COO, we are poised for substantial growth as we advance our mission to revolutionize drug discovery and development by testing on lab-grown human tissues to discover and develop new therapies for human diseases. https://lnkd.in/gQnP2JUF

We're thrilled to welcome Elliot Menschik as Vivodyne's CTO & board member to lead and further accelerate the advancement of our software, hardware, and AI/ML platform technologies. These pillars play a critical role in our mission to discover & develop better, safer drugs faster by testing on massive quantities of lab-grown human organs — yielding immediate human context from therapeutic program inception to completion.

#BiotechShowcase2024 Agenda Highlight! Looking forward to this panel discussion featuring Beth Rogozinski, Alex Aravanis MD PhD, Abraham Heifets, Andrei Georgescu, Ph.D., Kurt Thorn. See the full agenda here > https://bit.ly/3HUVTlp

Thanks to The Wall Street Journal and Brian Gormley for highlighting our work in their recent article! https://lnkd.in/eyue9m-b

Vivodyne in Freethink! Thanks Kristin Houser for speaking with CEO Andrei Georgescu, Ph.D. Biotech startup Vivodyne is planning to revolutionize drug development with an AI-powered #robot that can grow, dose, and analyze thousands of samples of human tissues at once. “The fundamental purpose of Vivodyne is to allow human testing [of drugs] on lab-grown human tissues before they get the clinical trials and are tested on real people,” CEO Andrei Georgescu told Freethink. “So it’s like human testing before testing on real people.” Read the full article below: https://lnkd.in/ePVU_QNY #drugdiscovery #drugdevelopment

https://lnkd.in/gUefUvwy